PanOptica eyes AMD opportunity with $30M series A round
This article was originally published in Scrip
Ophthalmology showed that it is still an attractive place for venture capitalists to put their money to work as PanOptica raised $30 million in a series A round led by SV Life Sciences and Third Rock Ventures. Some of the funds were immediately put to use as PanOptica licensed exclusive worldwide rights to PAN-90806, a small molecule selective inhibitor of vascular endothelial growth factor (VEGF) with potential as a topical treatment of neovascular age-related macular degeneration, from OSI Pharmaceuticals, a subsidiary of Astellas.
You may also be interested in...
Cambridge, UK-based Healx has concluded a $56m series B round, led by Atomico, to put up to 50 potential rare disease treatments into the clinic within two years using its AI/ML platform.
Tapping into the ability of arenaviruses to deliver prolonged local immune activation, rapid regression of localized and metastatic cancers, and long-term disease control, Essen, Germany-based start-up Abalos Therapeutics has raised €12m to advance its lead candidates towards clinical testing.
Celgene agrees to pay $75m upfront for options to three Immatics TCR-T targets for solid tumors. Deal could be worth up to $1.59bn to the German biotech, which also retains option to co-develop and co-fund certain licensed products.